Targovax ASA - Receipt of subscription rights in the rights issue by primary insiders and their close associates
Circio Holding ASA (CRNA) · publisert 2021-11-30 14:13 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| Abakus Invest AS nærstående | Closely associated person of Øystein Soug, primary insider in Targovax ASA | subscription | 235 022 | 0 NOK | 2021-11-30 | – | Outside a trading venue. Click or tap here to enter text. 2 Notification of transactions by primary insiders and their closely associated persons | rules · til gjennomgang |
| Magnus Jäderberg | CMO, Primary insider in Targovax ASA | subscription | 23 502 | 0 NOK | 2021-11-30 | – | Outside a trading venue. Click or tap here to enter text. 3 Notification of transactions by primary insiders and their closely associated persons | rules · til gjennomgang |
| Ingunn Munch Lindvig | VP RA, Primary insider in Targovax ASA | subscription | 11 751 | 0 NOK | 2021-11-30 | – | Outside a trading venue. Click or tap here to enter text. 4 Notification of transactions by primary insiders and their closely associated persons | rules · til gjennomgang |
| Victor Levitsky | CSO, Primary insider in Targovax ASA | subscription | 11 751 | 0 NOK | 2021-11-30 | – | Outside a trading venue. Click or tap here to enter text. 5 Notification of transactions by primary insiders and their closely associated persons | rules · til gjennomgang |
| Eva-Lotta Coulter | Board member, Primary insider in Targovax ASA | subscription | 60 363 | 0 NOK | 2021-11-30 | – | Outside a trading venue. Click or tap here to enter text. 6 Notification of transactions by primary insiders and their closely associated persons | rules · til gjennomgang |
| Robert Burns | Board member, Primary insider in Targovax ASA | subscription | 101 083 | 0 NOK | 2021-11-30 | – | Outside a trading venue. Click or tap here to enter text. 7 Notification of transactions by primary insiders and their closely associated persons | rules · til gjennomgang |
| Bente-Lill Romøren | Board member, Primary insider in Targovax ASA | subscription | 41 807 | 0 NOK | 2021-11-30 | – | Outside a trading venue. Click or tap here to enter text. 8 Notification of transactions by primary insiders and their closely associated persons | rules · til gjennomgang |
| Diane Mellett | Board member, Primary insider in Targovax ASA | subscription | 51 880 | 0 NOK | 2021-11-30 | – | Outside a trading venue. Click or tap here to enter text. 9 Notification of transactions by primary insiders and their closely associated persons | rules · til gjennomgang |
| Radiumhospitalets Forskningsstiftelse /Radforsk nærstående | Closely associated person of Bente-Lill Romøre, Primary insider in Targovax ASA | subscription | 5 202 529 | 0 NOK | 2021-11-30 | – | Outside a trading venue. | rules · til gjennomgang |
Vedlegg
- Notification_by_Primary_Insiders_301121.pdf (tekst hentet ut)
Meldingstekst
30 November 2021: Reference is made to the announcement made by Targovax ASA
(the "Company") earlier today, on 30 November 2021, regarding the commencement
of the subscription period for the rights issue (the "Rights Issue").
Please see the attached notifications of trade for information regarding the
primary insiders and their close associates who have received subscription
rights in the Rights Issue.
Notification by Primary Insiders
301121.pdf (https://mb.cision.com/Public/17093/3463524/911b5cee11aa0382.pdf)
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying its multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax's
focus is to "activate the patient's immune system to fight cancer", thus
extending and transforming the lives of cancer patients. Targovax's pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The company's product candidates are designed to harness the
patient's own immune system to fight the cancer, whilst also delivering a
favorable safety and tolerability profile.
Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both in monotherapy and in
multiple combinations, the next development steps for ONCOS-102 will be to
further improve responses in melanoma patients resistant to or poorly responsive
to current standard of care.